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【背 景】 近年我々は,グリオーマがIDH･TERT promoter
領域の遺伝子変異および染色体1p19q共欠失の有無に基
づき,分子遺伝学的に5つのグループ (Triple-Positive,
IDH Mutation Only,TERT Mutation Only,TERT and IDH Mutation,Triple-Negative)に分類されることを報告
した.この検討さらに発展させ,50の遺伝子変異とコピー
数異常の解析によって各グループ間の特徴的な異常を詳細




【結 果】 148例は,Triple-Positive 34例 (23％),IDH Mutation Only 40例 (27％),TERT Mutation Only 64例
(44％),TERT and IDH Mutation 6例 (4％),Triple-











22．Evaluation of Diffusion Weighted MR Imaging and
??F FDG PET for Monitoring Triple Negative Breast Cancer Response to Cisplatin Treatment Nguyen Thu Huong,Hirofumi Hanaoka,
Takahito Nakajima and Yoshito Tsushima
（Department of Diagnostic Radiology and Nuclear Medicine,Gunma University Gradu-
ate School of Medicine）
【Background】 The utility of platinum agents for triple negative breast cancer(TNBC)therapy is controversial since sometimes Cisplatin resistance occurs.In this study,
we planned to evaluate the usefulness of??F-FDG PET and difusion weighted MR imaging(DWI)as the early predic-
tor for Cisplatin treatment.【Methods】 Cisplatin was intraperitonealy injected into TNBC tumor bearing mice.
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